Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intestinal microbiota restoration refers to therapeutic interventions, such as fecal microbiota transplantation and microbiota restoration therapies, designed to re-establish a healthy balance and diversity of the gut microbiome. It is primarily used to treat recurrent Clostridioides difficile infection, is under investigation for other gastrointestinal and immune-mediated diseases, and functions by introducing beneficial microbes to outcompete pathogens, restore metabolic and immune functions, and enable gut homeostasis. This field is evolving, with approaches ranging from whole-stool transplantation to defined bacterial consortia and targeted small molecules or phage therapy, but "intestinal microbiota restoration" is a therapeutic principle, not a molecular or protein drug target.
Engraftment of beneficial microbial taxa to displace pathogenic microorganisms; Restoration of microbial diversity and functions; Inhibition of antibiotic-resistant organisms; Increase in beneficial metabolite production (e.g., short-chain fatty acids); Immune system modulation
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intestinal microbiota restoration.